Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.